## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($97.03)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. What to Expect From Revvityâ€™s Q4 2025 Earnings Report**
- Source: inkl | 20260105T100903 | Somewhat-Bearish | Relevance: 100%
- Revvity, Inc. (RVTY) is set to announce its Q4 2025 earnings, with analysts expecting an adjusted EPS of $1.54, an 8.5% increase from the previous year. Despite a robust earnings surprise history, the stock has underperformed the broader market, falling 12.4% over the past year due to weak constant-currency revenue growth and declining operating margins. Analysts maintain a "Moderate Buy" rating with a 16% upside potential, but caution remains due to a full valuation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +6.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 19.3x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.8B |
| Beta | 1.05 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 19.3 |
| Current P/E | 20.8 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.7% to 3.4% (+6.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.6pp (needs >4.0% for momentum thesis). MRS_5 at 3.6% confirms short-term momentum alignment. AM_20 at 3.5% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.36% (CS: 75) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 1.083x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $102.07
- **Stop Loss:** $97.03 (4.9% risk)
- **Target:** $112.15 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 171
- **Position Value:** $17,453.97
- **Portfolio %:** 17.45%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*